 |
|
|
| |
Rilpivirine Week 96 safety and efficacy by gender and race subgroups in treatment-naïve HIV-1-infected patients in the Phase III ECHO and THRIVE trials
|
| |
| |
Reported by Jules Levin IDSA Boston, MA Oct 20-22 2012
Claudia Martorell,1 Cynthia A Mayer,2 Esteban Ribera,3 Armin Rieger,4 Sharon Walmsley,5 Simon Vanveggel6 and Katia Boven7
1The Research Institute, Springfield, MA, USA; 2St. Joseph's Comprehensive Research Institute, Tampa, FL, USA; 3Hospital Vall D'Hebrón, Barcelona, Spain; 4Medical University of Vienna, Vienna, Austria; 5University Health Network, Toronto, ON, Canada; 6Tibotec BVBA, Beerse, Belgium; 7Tibotec Inc., Titusville, NJ, USA
|
| |
|
|
|
|
|
